beschikbaar?

TIP: soortgelijke CVs vinden

Interim Manager R&D [Pharma, Biotech]

Work Experience

Skills:
Versatile, operation- and result-oriented Life Science research manager with international experience in line-management obtained at renowned pharmaceutical companies. Convincing leadership skills, good communicator, interdisciplinary and innovation oriented.

Experience:
Startup of new projects, new departments, new company.
Turn Around Management
Strategic planning, finance planning, compilation of business plans

Defining und implementing research strategies, HR planning
Introducing new technologies, computerized systems, informatics tools, recruiting of specialists, international project management with licensors.
In-licensing and out-licensing, project wrap-up, outsourcing, restructuring, publication and patent strategies, allocation of scientific advisors

Supervision of biologist and chemists, identification of development leads, high-throughput screening, structure-assisted drug design, pharmacology, pharmacokinetics, animal models, immunology, gene therapy approaches.
IND pharmacology, strengthening interdisciplinary interactions.

Education

For details, see Sonstiges
Studies of Chemistry and Biology. Focus: molecular biology, biochemistry(NL; graduation with top 5%.
Univ. Doctorate (NL)
Post-Doctorate (USA);
Research Scientist (D)
Pharmaceitical R&D Management (S;USA; A)

Skills

Experience
Startup of new projects, new departments, new company.
Turn Around Management
Strategic planning, finance planning, compilation of business plans

Defining und implementing research strategies, HR planning
Introducing new technologies, computerized systems, informatics tools, recruiting of specialists, international project management with licensors.
In-licensing and out-licensing, project wrap-up, outsourcing, restructuring, publication and patent strategies, allocation of scientific advisors

Supervision of biologist and chemists, identification of development leads, high-throughput screening, structure-assisted drug design, pharmacology, pharmacokinetics, animal models, immunology, gene therapy approaches.
IND pharmacology, strengthening interdisciplinary interactions.

Languages

Dutch, English, German, Swedish

Other

Academic studies: 1966-1973.
Studies of Biology and Chemistry, University of Groningen, The Netherlands.
Doctoral degree (molecular biology and developmental plant biology) in 1973 ( c.l.; top 5%).

Academic Research: 1973-1982.
Research Scientist (Univ. of Groningen; HHMI Univ. of Miami, Fl. USA; Justus-Liebig Univ., Giessen, Germany)
Fields: Glyco-conjugates; viral glycoprotein biosynthesis.

Pharmaceutical Industry - Research Management: 1982-1998
Director, Exec Director (AstraZeneca, Bristol-Myers Squibb, Novartis)
Fields: Antiviral Chemotherapy
Genomics
General R&D management

Biotechnology Industry - Research Management: 1999-today
CSO, General Manager
Fields: Genomics
Immune Therapy
SPECIFICS re INDUSTRY POSITIONS

- ASTRA AB, Södertälje, Sweden (1982-1988). Director, Antiviral Therapy.
- BRISTOL-MYERS SQUIBB, Wallingford, Connecticut, USA, (1988-1991). Director Infectious Diseases-Antiviral Therapy.
- NOVARTIS RESEARCH INSTITUTE (NFI), Vienna, Austria (1991-1999). Executive Director Retroviral Diseases (-1994); Acting Head of the NFI (1994-1995); Head, Dept of Genetics (1995-1999).
- ARTEMIS-Pharmaceuticals, Köln, Germany (1999-2001). CSO, later with mission to start new company in the field of viral vector technology and immunotherapy. Since 2001 Manager of this new start-up “Methesys”.

Before joining Artemis Pharmaceuticals GmbH, I was Head of Genetics at the Novartis Research Institute in Vienna. My research program aimed at the discovery of drug targets and leads for skin diseases using the tools of molecular genetics and bioinformatics applied to dendritic cells. It was one of the first departments within Novartis dedicated to genomics and bioinformatics in drug discovery, and was based initially on a collaboration with the Max Planck Institut für Molekulare Genetik in Berlin.

During 1994, I was Acting Head of the Institute, then the Sandoz Research Institute (SFI) and, following the merger of Sandoz and CIBA, redirected the Institute’s focus to Dermatology. I joined the SFI in 1991 as Head of Retroviral Diseases, successfully leading a team of ca. 60 biologists and medicinal chemists in the discovery and profiling of novel drugs, focusing on non-classical targets for HIV therapy. The work resulted in some 60 publications, several patent applications and four development compounds, including one gene therapy product, and was based on extensive external collaborations with US-based companies (Systemix, Johnson-Matthey). One of my auxiliary activities was in Avalon Medical Partners, initiating the formation of new biotech companies in the USA.

Prior to joining the SFI, I was in charge of antiviral drug discovery programs at Bristol-Myers Squibb (USA) and Astra AB, now AstraZeneca (Sweden). At BMS, we initiated molecular virology programs linked to natural products screening and directed the profiling of antiviral nucleosides, including the now marketed products Zerit (HIV) and Cidofovir (CMV). At Astra, the group was one of the firsts world-wide to set up anti-HIV testing programs. The focus of the work was on anti-herpetics, including Foscavir, and the determination of the critical determinants of antiviral efficacy that are used to date in the pharmaceutical industry.

The author of over 60 research papers during my period of active research, I gained international reputation as an expert in antiviral chemotherapy. I have seventeen years of pharmaceutical industry experience in leading scientific management functions in three different companies. A citizen of The Netherlands, I studied biology and chemistry at the University of Groningen, from which I graduated Cum Laude (top 5%). I lived and worked in several European countries and in the USA, am married and have two children.

 beschikbaar?